GlassScriptPhysician profile
Lauren Scott
NPI 1376186403
$2,860.11
in general payments reported to CMS, 2019-2025
16 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.59 · 2022: $125 · 2023: $892 · 2024: $1,461 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $621.80 | 2024 | Manta |
| Regeneron Healthcare Solutions, INC. | $611.54 | 2023-2025 | Dupixent |
| Abbvie INC. | $588.80 | 2023-2024 | |
| Galderma Laboratories, L.P. | $207.47 | 2021-2023 | |
| Pfizer INC. | $193.18 | 2023-2024 | |
| Incyte Corporation | $132.69 | 2023 | Opzelura |
| Strata Skin Sciences, INC. | $116.64 | 2024-2025 | Xtrac |
| Genzyme Corporation | $114.86 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $80.45 | 2025 | Zoryve |
| Amgen INC. | $58.48 | 2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $28.99 | 2024 | |
| Biofrontera INC. | $26.03 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Revance Therapeutics, INC. | $22.53 | 2024 | Daxxify |
| Verrica Pharmaceuticals INC. | $22.47 | 2023 | Ycanth |
| Novartis Pharmaceuticals Corporation | $19.65 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $14.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.